Description:
Glucolipid Metabolic Disease (GMD) is an innovative journal that presents peer-reviewed clinical and scientific research on the identification, prevention, control, and treatment of glucolipid metabolic diseases (GLMD). Due to lifestyle changes in recent years, this chronic disorder has resulted... Show More
Glucolipid Metabolic Disease (GMD) is an innovative journal that presents peer-reviewed clinical and scientific research on the identification, prevention, control, and treatment of glucolipid metabolic diseases (GLMD). Due to lifestyle changes in recent years, this chronic disorder has resulted in an economic burden to healthcare systems around the world and poses a significant problem for public health. The ongoing prevalence of such metabolic diseases, with links to diabetes and obesity, indicates that current prevention and treatment methods are not working. Thus, it is imperative that finding new strategies to mitigate GLMD be undertaken by the world’s foremost experts.
Glucolipid Metabolic Disease (GMD) publishes these efforts through leading research articles, commentaries, and reviews that discuss all aspects of GLMD as well as its correlation with other risk factors such as cardiovascular diseases and neurological disorders. Crucially, the journal welcomes both Eastern and Western medical approaches, and a combination of thereof, to introduce groundbreaking prevention and treatment theory, pathogenesis, treatment strategy, drug research, and health management of metabolic diseases. This journal is vital for doctors, nutritionists, medical personnel, researchers, academicians, and students seeking the most up-to-date practices in this new field of medicine.
Mission & Scope:
Glucolipid Metabolic Disease (GMD) seeks to share the latest quality research encompassing all aspects of glucolipid metabolic diseases. As an international journal with global contributions and reach, it aims to blend Eastern and Western perspectives and practices to determine the best prevention and control methods for these types of disorders. In order to combat the rise of GLMD, alternative... Show More
Glucolipid Metabolic Disease (GMD) seeks to share the latest quality research encompassing all aspects of glucolipid metabolic diseases. As an international journal with global contributions and reach, it aims to blend Eastern and Western perspectives and practices to determine the best prevention and control methods for these types of disorders. In order to combat the rise of GLMD, alternative medicine and mainstream practices can be blended to achieve equitable health solutions and tout the highest form of inclusive medicine. Via this global collaboration, the journal aims to become the premier forum to solve GLMD across all countries and demographics.
Coverage:
- Alternative Medicine
- Arteriosclerotic Cardiovascular and Cerebrovascular Diseases
- Chronic Disorders
- Complementary Medicine
- Diabetes
- Dyslipidemia
- Eastern Medicine
- Epidemiology
- Glucolipid Metabolic Diseases
- Glucolipid Metabolism
- Glycolipid Metabolic Diseases
- Hyperglycemia
- Inflammation
- Insulin Resistance
- Integrative Medicine
- Intestinal Flora Disorders
- Metabolic Disorders
- Neuroendocrine Disorders
- Neurological Diseases
- Non-Alcoholic Fatty Liver Disease
- Obesity
- Oxidative Stress
- Pathogenesis
- Public Health
- Traditional Medicine
- Western Medicine
Editorial Board
Editorial Board is currently being developed.
IGI Global holds its journals to the highest ethical practices.
View Full Editorial PolicyArticle Processing Charge (APC):
Payment of the APC fee (directly to the publisher) by the author or a funding body is not required until AFTER the manuscript has gone through
the full double-blind peer review process and the Editor(s)-in-Chief at his/her/their full discretion has/have decided to accept the manuscript based
on the results of the double-blind peer review process.
Please note that IGI Global cannot schedule the article for publication or publish the article until payment has been received. It is also important to note that in scholarly publishing, utilizing an open access journal's resources and time with no intent to pay the open access Article Processing Charge (APC) if the article manuscript is accepted following the peer review process is considered to be unethical and exploitative.
What Does IGI Global's Open Access APC Cover?
In the traditional subscription-based model, the cost to the publisher to produce each article is covered by the revenue generated by journal subscriptions.
Under OA, all the articles are published under a Creative Commons (CC BY) license; therefore, the authors or funding body will pay a one-time
article processing charge (APC) to offset the costs of all of the activities associated with the publication of the article manuscript, including:
- Digital tools used to support the manuscript management and review process
- Typesetting, formatting and layout
- Online hosting
- Submission of the journal's content to numerous abstracts, directories, and indexes
- Third-party software (e.g. plagiarism checks)
- Editorial support which includes manuscript tracking, communications, submission guideline checks, and communications with authors and reviewers
- All promotional support and activities which include metadata distribution, press releases, promotional communications, web content, ads, fliers, brochures, postcards, etc. for the journal and its published contents
- The fact that all published articles will be freely accessible and able to be posted and disseminated widely by
the authors - Professional line-by-line English language copy editing and proofreading*
*This service is only performed on article manuscripts with fully paid (not discounted or waived) APC fees.
APC Subsidizing and Funding
To assist researchers in covering the costs of the APC in OA publishing, there are various sources of OA funding.
Additionally, unlike many other publishers, IGI Global offers flexible subsidies, 100% Open Access APC funding, discounts, and more.
Learn More
IGI Global recognizes that many researchers may not know where to begin when searching for OA funding opportunities. IGI Global recently launched an
Open Access Funding Resources page for researchers to browse.
This page provides a comprehensive list of OA funding sources available for researchers to secure funds for their various OA publications.
This journal is currently actively seeking new submissions. Interested authors should ensure that their article manuscript adheres to the journal's
submission guidelines
and utilize the
journal article template,
which include originality of the manuscript, professional English language copy editing, APA formatting tips, and more. To submit an article for consideration, please begin the submission process below.
All inquiries regarding GMD should be directed to the attention of:
Dr. Jiao GuoGuangdong Pharmaceutical University, China
Editor-in-ChiefGlucolipid Metabolic Disease (GMD)&
Alexis MillerIGI Global
Journal Development CoordinatorGlucolipid Metabolic Disease (GMD)Email:
gmd-editorial-team@igi-global.com
All of IGI Global's content is archived via the CLOCKSS and LOCKSS initiative. Additionally, all IGI Global published content is available in
IGI Global's InfoSci® platform.